Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female Subjects able to give consent~* Post partum patients~* Baseline Hbg\< /= 10~* Agree to practice birth control~* Demonstrate willingness to comply with protocol restrictions~Exclusion Criteria:~* Known hypersensitivity reaction to oral or IV iron (VIT-45)~* Documented history of discontinuing oral iron~* Significant bleeding~* History of anemia other that iron deficiency anemia~* Severe Psychiatric disorders~* Active severe infection~* Known Hepatitis B antigen or Hep C viral antibody or active hepatitis~* Known HIV antibody~* Received investigational product within 30 days~* Alcohol abuse~* Hemochromatosis or other iron storage disorder

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VIT-45 (Type: EXPERIMENTAL): A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
- Oral iron tablets (Type: ACTIVE_COMPARATOR): 325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42

Based on this trial design, predict the completion outcome and termination type (if applicable).